Clinical studies of antisense oligonucleotides for cancer therapy.
Orr
Rosanne M
RM
Cancer Research UK Centre for Cancer Therapeutic, The Institute of Cancer Research, Sutton, Surrey, UK.
Dorr
F Andrew
FA
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017868:Cyclic AMP-Dependent Protein Kinases / Q000235:genetics; D015254:DNA Modification Methylases / Q000235:genetics; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000235:genetics; D051571:Protein Kinase C-alpha; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D020598:Proto-Oncogene Proteins c-myb / Q000235:genetics; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics; D012264:Ribonucleotide Reductases / Q000235:genetics
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D020598:Proto-Oncogene Proteins c-myb; D012264:Ribonucleotide Reductases; D015254:DNA Modification Methylases; D019908:Proto-Oncogene Proteins c-raf; D017868:Cyclic AMP-Dependent Protein Kinases; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha